Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Mitsubishi Tanabe, SOBI - LARVOL DELTA

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR) (ASH 2025) - P1 | "Exploratory endpoints include duration of response, progression-free survival, and overall survival. Correlative analysis includes minimal residual disease testing on banked diagnostic tissue and CSF from different timepoints."

Clinical • P1 data • Surgery • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • CNS Lymphoma • CNS Tumor • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Pattern of infections and impact on immunocompetence of next generation B-cell depleting immunotherapies in non-Hodgkin's lymphomas: Results from a multicentre retrospective real- life cohort. (ASH 2025) - "All patients diagnosed with NHL in three Italian centers, who started thetreatment from Dec 1st, 2019 to Apr 30th, 2025 were consecutively included in the analysis. 110 NHL patients were treated with 131 lines of immunotherapies, including 91 with antiCD19CAR-T cells (46 Axi-cel, 29 Tisa-cel, 16 Brexu-cel), 30 with antiCD20/antiCD3 bispecific MoAbs (10glofitamab, 14 epcoritamab and 6 mosunetuzumab), and 10 with AntiCD19 ADC (loncastuximab). Infections are common complications during novel immunotherapy treatments in NHL:nonetheless, in our real-life cohort most of cases occurred early (< 100 days) and showed manageablemild-moderate severity. Overall, in this setting of relapsed/refractory NHL patients the main cause ofdeath remains lymphoma progression."

Retrospective data • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Mediastinal Large B-Cell Lymphoma • Respiratory Diseases

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial (ASH 2025) - P2 | "Median age was 74 (range, 45-84),8 (80%) were male, 6 (60%) had received axicabtagene ciloleucel and 4 (40%) had received lisocabtagenemaraleucel. This study will continue to enroll another 10 patients to achieve the secondinterim futility analysis. Correlative analyses will include serial assessment of minimum residual diseaseand descriptive analysis of tumor molecular biology, including DNA and RNA sequencing."

Clinical • P2 data • B Cell Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis (ASH 2025) - "The safety profileobserved was consistent with known toxicities and was manageable in routine clinical practice with nonew signals detected. Lonca is currently explored in earlier lines and in combination in ongoing clinicalstudies."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Leukopenia • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma • BCL2

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models (ASH 2025) - "Patients receiving subsequent treatment showed a trend towardimproved survival compared to those without further treatment with median OS of 9.95 months versus0.76 months, respectively.Among patients receiving subsequent therapy, the most common treatments were polatuzumabvedotin-based regimens (18%), followed by bispecific antibodies (13%; glofitamab or epcoritamab),radiotherapy alone (13%), anti-CD19 therapies (6%; tafasitamab or loncastuximab), other targetedtreatments (12%), and salvage chemotherapy ± rituximab (7%).The highest complete response (CR) rates were achieved with bispecific antibodies (38%), followed byanti-CD19 agents (33%) and polatuzumab-based regimens (27.8%). The identified prognostic factors and prediction model mayassist clinicians in patient counseling. Further research is needed to optimize therapeutic strategies forthese challenging patients."

Biomarker • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Effect of prior CD19-directed monoclonal antibody exposure on outcomes in patients subsequently treated with CD19 targeting CAR-T therapy: A multicenter propensity score matched retrospective cohort study (ASH 2025) - "CD-19-directed monoclonalantibodies (CD19-mAb), such as tafasitamab and loncastuximab tesirine, are increasingly used inrelapsed or refractory B‑cell lymphomas. However, the relatively small sample size after PSM, limits thisstudy and warrants cautious interpretation. These results highlight the need for careful consideration ofprior CD19-directed therapies when planning CAR-T treatment and underscore the importance ofprospective studies to optimize sequencing strategies and improve patient outcomes."

Retrospective data • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers (ASH 2025) - "In this large RWDA of Lonca, pts who achieved any form of clinical response experienced asignificantly longer OS than previously reported for heavily pre-treated pts. Lonca was predominantlyadministered after TCET; however, there was no significant difference in efficacy between pts whoreceived CART and BsAbs and those who did not. CD19 positivity and earlier utilization of Lonca did notappear to have an impact on response rates."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pruritus • Respiratory Diseases • Thrombocytopenia • CD19 • TINCR

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma (ASH 2025) - "Most common CART product was axi-cel (56%), followedby tisa-cel (21%), liso-cel (22%), and others (1%).73 pts received BsAbs ,with BsAb monotherapy (B-M) in 60 pts and BsAb + targeted therapy (B+T) in 13pts. Non-BsAb regimens (n=238) included chemoimmunotherapy (CIT, n=45), lenalidomide +/-tafasitamab (len +/-taf, n=75), polatuzumab-bendamustine-rituximab (pola-BR; n=48), checkpointinhibitors (CPI, n=25), loncastuximab (lonca, n=7) or other targeted therapies (TT, n=38).Baseline characteristics were balanced between the B-M and non-BsAb groups, including age, sex, cell oforigin, double-hit lymphoma (DHL), primary refractory disease to frontline CIT (PRD), prior autologoustransplant, prior bendamustine, and time to salvage <90 days post–CAR-T...Treatment-era bias may affect results, as manynon-BsAb pts were potentially treated before BsAb FDA approval, but our results support integration ofBsAbs in the post-CART setting. Prospective validation is warranted to define..."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia. (ASH 2025) - P2 | "Our findings from this ongoing, prospective trial demonstrate a high VGPR/CR rate of 71% inheavily pre-treated WM. Notable, is the VGPR/CR rate of 89% in high-risk patients with TP53ALT WM. Nounexpected toxicities have been seen in this trial."

Clinical • Hematological Disorders • Lymphoma • Lymphoplasmacytic Lymphoma • Waldenstrom Macroglobulinemia • CA6 • CXCR4 • MYD88 • TP53

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need (ASH 2025) - "Epcoritamab and glofitamab were administered in20 (63%) and 12 (37%) pts, respectively, with a median treatment duration of 1.5 months (IQR 0.7–3.3).The best overall response rate (ORR) to BsAb was 25%, comprising 2 complete responses (CR) and 6partial responses (PR)...Theremaining 12 (37%) did not receive additional treatment due to deteriorating clinical status or death.Subsequent treatment types included clinical trial (n=5, 25%), chemotherapy (n=5, 25%), loncastuximabtesirine (lonca-T, n=4, 20%), tafasitamab ± lenalidomide (n=2, 10%), first-time CAR-T (n=2, 10%),polatuzumab-based therapy (n=1, 5%), radiation (n=1, 5%), and a second BsAb regimen of glofitamab-GemOx (n=1, 5%)...Pts with R/R LBCL after BsAb therapy represent a new, urgent unmet medical need. Given ourlimited sample size, these findings warrant validation in a larger study."

Clinical • IO biomarker • B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303. (ASH 2025) - "Lonca-R followed by DA-R-EPOCH appears to be a promising regimen for patients with DHLand/or DEL. ORR was >80% in patients who had completed at least 2 cycles, and 100% if all 8 cycles werecomplete. Median PFS and OS were not reached."

Clinical • P2 data • B Cell Lymphoma • Diabetes • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study (ASH 2025) - "The most commonly-used next line of systemic therapies included: loncastuximab tesirine in 19pts (ORR 16.7%, all PR); commercial CAR T in 11 pts (ORR 50% [CR 36.4%, PR 18.2%); tafasitamab withlenalidomide in 7 (no responses); and other chemotherapy in 46 pts (ORR 27.6% [CR 24.1%]). We report the outcomes of largest cohort of pts with POD post-BsAbs in r/r LBCL.Progression events occurred early after initiation of single agent BsAbs, and almost half of pts whoprogressed did not receive subsequent therapy. For those who received standard subsequent-linetherapy after POD, response rates and survival outcomes were poor. Pts with POD after BsAB should bestrongly considered for clinical trials of novel therapeutics or combination therapies."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PRNewswire) - "Best overall response rate (ORR) was 89.8% (44/49 patients) as assessed by Lugano criteria Complete response (CR) rate was 77.6% (38/49 patients). Of these, 33/38 patients achieving CR remain in CR as of the data cutoff....Strong efficacy in both the relapsed and primary refractory populations across both dose levels. In the 24 relapsed patients ORR was 100% and CR rate was 91.7%. In the 25 primary refractory patients ORR was 80% and CR rate was 64%. 14 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 13 patients respectively)....LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026."

Enrollment status • P1 data • Diffuse Large B Cell Lymphoma

ADC Therapeutics SA…announced that it will host a conference call and live webcast on Wednesday, December 3, 2025…to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in patients with…r/r DLBCL (ADC Therapeutics Press Release)

P1 data • Diffuse Large B Cell Lymphoma

Targeted DNA Damage Boost with Loncastuximab Tesirine in Combination with PARP Inhibitors in Diffuse Large B-Cell Lymphoma (ASH 2023) - "Similar results were obtained by combining Talazoparib and different PARP inhibitors with the alkylating agent cisplatin, indicating a class effect. Importantly, PBMC-derived T cells from healthy donors did not show any sign of DNA damage accumulation upon exposure to Lonca, Talazoparib and the combination. These data provide the rationale for future therapeutic strategies based on selective induction of DNA damage in neoplastic B cells in combination with DDR inhibition in aggressive MYC-positive B cell lymphoma."

Combination therapy • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • AURKA • BCL2 • BRCA • BRCA2 • CASP3 • CASP7 • H2BC8 • MYC • TP53

Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study (ASH 2024) - P2 | "Premedication with dexamethasone 4 mg twice daily for 3 days and prophylaxis with spironolactone 100 mg (to prevent fluid overload) was required...At the time of study design, the best reported CR rate in r/r MZL was 16% achieved with umbralisib, that we used as P0 assumption under the null hypothesis...Across all lines of treatment, the most common treatments were R-chemotherapy (n=18), targeted/immuno-modulatory agents (n=7) and single-agent rituximab (n=7); 1 patient had CAR-T...The patient clinically fully recovered with normalization in LFTs abnormalities. Conclusion : Lonca is demonstrating clinically meaningful activity with robust CR rate in r/r MZL patients in our ongoing phase 2 study."

Clinical • IO biomarker • P2 data • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma (ASH 2024) - "Enrollment continues in a dose expansion cohort that also includes patients with r/r mantle cell lymphoma. Updated analyses with longer follow-up and expanded enrollment will be presented."

Clinical • Combination therapy • Acute Kidney Injury • Anemia • Atrial Fibrillation • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypotension • Infectious Disease • Leukopenia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Thrombocytopenia • Waldenstrom Macroglobulinemia

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis (ASH 2023) - "Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine (Lonca), polatuzumab vedotin + bendamustine + rituximab (Pola-BR), rituximab + gemcitabine + oxaliplatin (R-GemOx), tafasitamab + lenalidomide, and epcoritamab. Over 3 years, the estimated cumulative per-patient cost of glofitamab is projected to be the lowest when compared with per-patient costs of other available T-cell engaging therapies, resulting in cost savings after its formulary adoption for the treatment of R/R DLBCL after ≥2 lines of therapy."

HEOR • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment (ASH 2023) - "Fifteen (31%) pts received drugs traditionally restricted to outpatient use only (daratumumab (10), carfilzomib (3), obinutuzumab (1), loncastuximab tesirine (1), polatuzumab vedotin (1)). In this retrospective analysis, about a quarter of pts with lymphoid and plasma cell malignancies were alive at 5 months after receiving unplanned inpatient antineoplastic therapy. Better tools are needed to select pts who may benefit from urgent inpatient treatment, as a small subset of our cohort experienced continued clinical benefit. Combining such tools with multidisciplinary discussions may help to maximize favorable outcomes while minimizing use of aggressive end-of-life antineoplastic treatment."

Clinical • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Plasmacytoma • Prolymphocytic Leukemia • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (ASH 2023) - P1/2, P2 | "Lonca demonstrated substantial and clinically meaningful single-agent efficacy and was well-tolerated in heavily pretreated Chinese patients with R/R DLBCL. Toxicities were generally manageable and reversible in most patients by routine clinical practice and/or with dose modifications, with neither unexpected safety concerns nor different toxicity profile in patients aged ≥65 years. Encouraging and durable responses were also observed in high-risk patient groups, including patients with advanced stage, transformed or refractory DLBCL."

Clinical • Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma – a Phase 2 Study (ASH 2023) - P2 | "Premedication with dexamethasone 4 mg twice daily for 3 days was required with loncastuximab...R-CHOP was most common first-line therapy (n=14; 54%) followed by bendamustine with rituximab and single-agent rituximab (n=6; 23%; each)... A limited duration program combining loncastuximab with rituximab in patients with rel/ref FL is well tolerated and highly effective with a metabolic CR rate of 86% including high-risk patients with POD24 and/or high disease burden."

P2 data • B Cell Lymphoma • Biliary Cancer • Cholangiocarcinoma • Dermatology • Diffuse Large B Cell Lymphoma • Fatigue • Follicular Lymphoma • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study (ASH 2024) - P=N/A | "Background : Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly utilized chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), especially for patients ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor T cell therapy (CAR T). R-GemOx is used as a comparator arm in several active phase III clinical trials for R/R DLBCL, including the POLARGO (polatuzumab vedotion and R-GemOx), STARGLO (glofitamab and GemOx), SUNMO (mosunetuzumab and polatuzumab vedotin), LOTIS-5 (loncastuximab tesirine and rituximab), and EPCORE DLBCL-1 (epcoritamab) studies...This study demonstrates real-world evidence of the efficacy of R-GemOx in a large cohort of patients with R/R DLBCL from the US over a long period, including both transplant-eligible and -ineligible patients, and patients treated in the CAR T era. These data aid in providing a benchmark for active clinical trials in the rapidly evolving..."

Retrospective data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Systematic Literature Review of Clinical Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated in the Third-Line or Later Setting (ASH 2024) - "Treatments included bendamustine + rituximab (BR; n=1), bispecific antibodies (epcoritamab, n=1; glofitamab, n=1), CAR T-cell therapies (axicabtagene ciloleucel, n=1; tisagenlecleucel, n=1; lisocabtagene maraleucel, n=1), loncastuximab tesirine (n=2), polatuzumab + BR (n=1), selinexor (n=2), and tafasitamab (anti-CD19 monoclonal antibody) + lenalidomide (n=1). While interventions identified were evaluated in patients receiving a third or later LOT, treatments such as CAR T-cell therapies, bispecifics, and polatuzumab are now recommended or being studied in earlier LOT, leaving limited third-line options and a lack of standard of care. RCTs such as the ECHELON-3 trial, comparing brentuximab vedotin vs placebo, both in conjunction with lenalidomide and rituximab, in patients with R/R DLBCL, are needed to evaluate the efficacy and safety of new third-line treatment options for patients with R/R DLBCL."

Clinical • Clinical data • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

What is established in the treatment of diffuse large B-cell lymphoma? (PubMed, Inn Med (Heidelb)) - "First-line standard therapy is R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), de-escalated to four cycles for young, low-risk patients (FLYER trial)...In relapsed/refractory disease, chimeric antigen receptor (CAR) T‑cell therapy with axicabtagene ciloleucel or lisocabtagene maraleucel has replaced high-dose chemotherapy with autologous stem cell transplantation for refractory or early relapses, including transplant-ineligible patients. Additional antibody-based therapies-such as polatuzumab-bendamustine-rituximab, tafasitamab-lenalidomide, loncastuximab, and bispecific antibodies (glofitamab, epcoritamab, odronextamab)-expand treatment options, some achieving durable remissions. Glofitamab plus gemcitabine-oxaliplatin is a new standard for first relapse when CAR T‑cell therapy is not feasible or as bridging before CAR T. Future directions include earlier integration of immunotherapies, personalized strategies guided by genetic..."

Journal • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Bridging HTA and Reimbursement: Navigating Diffuse Large B-Cell Lymphoma Interventions between Regulatory Frameworks and Cost Coverage in German Cancer Centers (DGHO 2025) - "These include chemotherapeutic regimens like Rituximab-Gemcitabine-Oxaliplatin (R-GemOx), CAR-T therapies (Axicabtagene ciloleucel [axi-cel], Lisocabtagene maraleucel [liso-cel], Tisagenlecleucel [tisa-cel]), targeted therapies (Polatuzumab-Bendamustine-Rituximab [pola-BR], Tafasitamab-Lenalidomide [Tafa-L], Loncastuximab tesirine), and bispecific antibodies such as Glofitamab. The EF method applied in Germany identifies the most favorable incremental cost-effectiveness ratios (ICER) for DLBCL treatments. Recent decisions on pricing could shift certain non-dominant EF strategies. To ensure value-based patient access to innovations, it is crucial to align health technology assessment (HTA) regulations and reimbursement policies, particularly in the inpatient sector, from a monetary incentive standpoint."

Reimbursement • US reimbursement • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology